The payment is tied to elritercept, which Keros is developing as a blood platelet producer. The drug reached a clinical-trial milestone with the first patient completing dosing.
Keros said the buyback authorization may be modified or discontinued at any time.

Comments (0)
No comments yet. Be the first!